Daily syntheses of primary biopharma news, stock indicators, volume anomalies, and market-moving events.
Monday's file adds eleven items compiled from public sources, led by three licensing/acquisition moves (Shionogi–IntraBio, Genentech–Alector, CSL–Alentis), the 2026 Nobel Prize in Medicine for optogenetics, and a regulatory mix spanning an Abbott heart-failure approval, a first interchangeable Xolair biosimilar, and an FDA review delay for Novo's hemophilia candidate.
Saturday's file adds four items compiled from public sources: an FDA label expansion for Lilly's Jaypirca into first-line CLL, Bayer's $2.2B Ohio manufacturing build-out, a Phase 3 disappointment for Zealand's Boehringer-partnered obesity drug, and a streamlined NIH public-information site. A quiet day after a deal-heavy week.
Friday's harvest lands 25 items across ten sources: Novartis's $7.8B mRNA T cell engager deal with China's Abogen, Sanofi's $1B expansion of its Regeneron alliance, an FDA first-in-class heart valve approval, a Phase 3 win for Taiho and a 166% single-day move in Kodiak Sciences. Add a biosimilar pact, an immunotherapy wind-down and a heavy public-health file.
29 items from seven free sources. The day splits three ways: a workforce cluster (Foghorn shedding 40% of staff after its Lilly collaboration collapsed, plus cuts at BioMarin and Novo Nordisk), a regulatory cluster led by an FDA warning letter for a Fresenius Kabi plant and fresh FDA moves on trial modernization and advisory committees, and a business block anchored by Sanofi's $1B upfront payment to Regeneron and Varda's $251M Series D for orbital drug manufacturing.
35 items from seven free sources. The day is dominated by metabolic data — Lilly's retatrutide and amylin-GIP/GLP-1 combinations, Roche and Zealand's amylin dose finding, and Novo–Lilly dataset sparring at EASD — followed by immunology readouts (Amgen, Merck, Connect Biopharma), two FDA newsroom announcements, and a business block built on reshoring, tariff rules and radiopharma funding.
51 items from nine free sources spanning Sept. 1–29, after a backlog cleared in the MedCity and PR Newswire feeds. The batch splits into FDA decisions (AbbVie's Parkinson's approval, Mirum, Ultragenyx, Scholar Rock, Roche), China-facing dealmaking (Lilly–InnoCare, Novo–Hengrui, Merck–SciBrunch), a $2B AstraZeneca stake in Summit, four biotech listings, and a Roche obesity retreat.
Fourteen items from five free sources — BioSpace, Fierce Biotech, Fierce Pharma, Pharmaphorum and the PR Newswire FDA feed. The day splits into FDA decisions (AbbVie's tavapadon approval, a withdrawn Daiichi Sankyo filing, a Lupin tentative approval), a cluster of China- and Japan-facing dealmaking, three clinical readouts, and one government-funded antifungal contract.
Seven items from three free sources — Pharmaphorum, BioSpace and the PR Newswire FDA feed. An EU first for a rare neurodegenerative disease, a speedy FDA review for Imfinzi in bladder cancer, a phase 3 win for MSD's return to ophthalmology, five-year survival follow-up for Carvykti, and three device-side clinical and clearance milestones.
Nine items from four free sources — Fierce Pharma, Fierce Biotech, BioSpace, FDA Newsroom and Pharmaphorum. An ultra-rare bone lesion approval for Mirum, a UK watchdog rebuke of Lilly's GLP-1 messaging, a $440M T-cell engager carve-out between Henlius and Amberstone, and a pair of AI-in-biopharma stories on hiring and on Medicare data.
Seventeen items from BioSpace, Fierce Pharma, Fierce Biotech and BioPharma Dive: FDA approvals for Lilly's once-weekly insulin Onswik and Merck's Welireg-Lenvima kidney cancer combo, Novo's $1.3B delivery deal with Nanexa, a $90M jury verdict for Nektar against Lilly, and a widening biotech IPO window.
Thursday's harvest produced seventeen items across five sources. Eli Lilly's once-weekly insulin won FDA clearance and its CEO claimed roughly 70% of the Medicare GLP-1 market, Merck's experimental eye drug matched Roche's VEGF inhibitor while drawing safety questions, Kyverna said long-term CAR-T data support an FDA submission, and an FDA advisory committee voted in favor of GRAIL's Galleri test. Two China-linked deals and a $522 billion national biotech target rounded out the day.
Wednesday's harvest produced twenty-one items across six sources. Immunovant's IMVT-1402 failed a phase 2b cutaneous lupus study, Roche's phase 3 kidney win opened an accelerated-approval path, and AI-driven discovery pulled in a $311M Series E for Enveda and a $140M Series C for Basecamp Research. Diagnostic and delivery milestones landed from Werfen, Persista Bio and Sagent, while BMS added another 265 New Jersey layoffs and nine European board chairs warned about the bloc's R&D footing.
Tuesday's harvest produced twenty-five items across seven sources, the largest batch in weeks. IntraBio won the first global approval for ataxia-telangiectasia, Amgen's dazodalibep posted a phase 3 win in Sjögren's, and phase 2b kidney data from Vertex landed alongside ALS and bipolar mania readouts. Dealmaking returned with Lexeo's Mantle acquisition and a Boehringer-Envisagenics AI oncology pact, Iambic filed for an IPO, and Novo disclosed a 13,000-person workforce reduction as it released low-dose CagriSema data.
Fifteen items made it through today's harvest, led by Telix's $1.65B purchase of ITM Isotope Technologies Munich and Bayer's offload of Stivarga to Grunenthal. Clinical readouts from Cue Biopharma, Alkermes and Beacon Therapeutics, four FDA regulatory moves (including a rule on animal-testing alternatives), an AI discovery platform release from Iambic and Novartis-adjacent dealmaking round out a batch that finally broke the multi-day saturation pattern.
Today's harvest is a compact regulatory set: SMSbiotech's FDA go-ahead for inhaled allogeneic stem cells in COPD, KELLS' Singapore HSA registration for an AI dental screening tool, Olatec's clinical leadership additions alongside its Phase 2 Parkinson's program, and Acurx's in vitro C. difficile data. The trade press added no stories the collection had not already captured.
Saturday's harvest adds 14 items across six sources. The lead regulatory notes are an FDA approval for Eli Lilly's oral SERD combination in second-line breast cancer and a European CHMP round covering eight medicines. Around them: two China-policy threads, three capital-markets filings, an obesity-drug licensing deal, and a pair of device reimbursement and access milestones.
Friday's harvest adds 18 items across seven sources. The lead story is an FDA green light for the first gene therapy in Sanfilippo syndrome type A, the latest in a run of first-in-class rare-disease approvals. Around it: a widening agency-level debate over Chinese biotech, a fresh run of reverse mergers, two prominent clinical and programmatic reversals, and a cluster of capital-markets and diagnostics milestones.
Thursday's harvest adds 19 items across six sources. The headline thread is bispecific and macrocycle platform dealmaking — Roche committing up to $1B to Dualitas and Novo backing Orbis in a pact worth up to $1.4B — alongside an unusually steady run of FDA approvals and clearances, a pair of executive appointments, and a biosimilar patent fight. Setbacks and second acts round out the batch with Longeveron's mid-stage stem cell miss and Lisata's merger lifeline.
Wednesday's harvest brings 22 items across ten sources. Three themes dominate: a rough stretch for Novartis (a Phase 2 ALS failure, a $125M bolt-on acquisition, and pressure on muscle-disease peers), an unusually process-heavy FDA week (a first radioligand generic, a warning letter, a rare-disease trial workshop, and a psychedelics/PDUFA forum), and continued AI dealmaking including a Novo–Anthropic partnership. Financing and manufacturing news round out the batch with Sling's $123M Series C, Ori's $120M accord, and Sionna's deep cuts.
FDA launches Operation TrialBlazer to expedite early-stage drug trials. GSK strikes a $750M deal for Chimagen's T-cell engager and winds down a German vaccine factory. Novo Nordisk rebrands and scraps an Ascendis GLP-1 pact. Lilly signs a $237M CNS gene-therapy collab. Scholar Rock wins first-in-class SMA approval. Multiple Phase 2 failures from J&J-Contineum, Axoltis, and AstraZeneca's newly approved breast cancer pill.
Scholar Rock wins first FDA approval for SMA, Novo Nordisk drops 'Nordisk' in major rebrand, Definium notches third Phase 3 LSD win, Electra eyes $342M IPO, and AstraZeneca's SERD disappoints in advanced breast cancer.
Eight articles spanning FDA regulatory delays for Exelixis, AdJane's mucosal vaccine platform, cyclospora outbreak resolution, Medicaid policy shifts, biotech venture capital expansion, and macular degeneration research grants.
Today's harvest covers Takeda's R&D chief retirement, Novartis facing investor pressure after M&A misfires, FDA's regulatory flexibility on psychedelics, Samsung Biologics' manufacturing deals, and new clinical developments across the biopharma landscape.
Biohaven's epilepsy drug faces another FDA hold, Frazier Life Sciences raises $1.1B, and Takeda's R&D chief announces retirement. Plus FDA leadership solidifies at CDER and CBER, Encoded Therapeutics closes $275M for Dravet gene therapy, and Kura Oncology spins out a Lilly-backed diabetes play.
44 articles from 8 sources covering FDA leadership confirmations, a wave of AI-bio partnerships (ARPA-H, Anthropic), major funding rounds (Encoded $275M, Solstice $225M, Moonwalk $70M), and several pivotal clinical wins including BMS's myeloma CAR-T and Amgen's Imdelltra in SCLC.
AstraZeneca's surprise oral SERD approval headlines a busy Monday with Novo Nordisk's Wegovy pediatric data, Novartis's dual Phase 3 setbacks, and fresh capital flowing to obesity-focused biotechs like Moonwalk Bio. FDA activity spans oncology, cardiology, and rare disease, while CAR-T pioneer BrainChild Bio secures $116M for pediatric brain cancer trials.
Six items from five sources covering Novo Nordisk and Novartis Phase 3 misses, ADARx's IPO plans, Claret's European fund expansion, GSK's Hutchmed acquisition, and a new cardiac monitoring device.
Ionis secures FDA approval for Alexander disease, Novartis halts CAR-T trial after patient deaths, ADARx files for IPO with AbbVie backing, and GSK licenses HUTCHMED's cancer drug for $110M.
Today's harvest covers11 articles from8 sources including FDA approvals for Ionis and a breast cancer treatment, Novartis Lp(a) Phase 3 failure, Pfizer's continued Seagen ADC divestment, and new product launches from Withings.
Novartis halts CAR-T trials after patient deaths, Menarini secures European GLP-1 rights for $771M, Ionis wins first FDA approval for Alexander disease, and Roche partners with Simcere on a $1.53B autoimmune trispecific deal. Plus White House drug pricing expansion and AbbVie's Phase 3 myeloma win.
25 articles from 7 sources covering Akeso/Summit's ivonescimab Phase 3 win over Keytruda, GSK's $1.3B Hutchmed licensing deal for KRAS-EGFR cancer therapy, Ultragenyx's failed Angelman syndrome trial, FDA regulatory actions on foreign inspections and botanical drugs, and continued biopharma workforce restructuring.
uniQure files for the first Huntington's gene therapy approval, FDA clears a pediatric neurodegenerative trial, BMS faces potential 'carnage' without its AstraZeneca safety net, Novartis' Rhapsido posts clean MS data, and biopharma reverse mergers spike 1,600% in Q3. Roche signs a $1.5B Asia deal, BioXcel enters bankruptcy, and GSK's mRNA flu vaccine advances to pivotal testing.
Three deaths in autoimmune CAR-T trials trigger Novartis to halt studies and Bristol Myers Squibb to follow suit, casting a shadow over one of biotech's hottest modalities. Roche signs a $1.53B deal with Simcere for a B-cell antibody, GSK's mRNA flu vaccine clears a path to Phase 3, and the White House unveils nine new MFN drug pricing deals with midsize biotechs. Novartis' BTK inhibitor Rhapsido posts clean Phase 3 MS data without liver safety signals, while Alumis' TYK2 pill stumbles in lupus. ArsenalBio sheds most staff in a pivot to in vivo CAR-T, and ARCH Venture Partners targets a $3 billion fundraise.
Eli Lilly's acquisition of Merida Biosciences for up to $2.9B dominates the Sunday headlines, alongside FDA approvals for Revolution Medicines' KRAS inhibitor in pancreatic cancer, Takeda and Protagonist's first-in-class treatment for rare blood cancer, and Roivant's Lisraya. Clinical readouts from AstraZeneca and Arrowhead, Samsung Biologics' PolyPeptide takeover bid, and ongoing debate over Medicare drug price negotiations round out the day's 38-article harvest from eight sources.
Three FDA approvals headline the day's harvest — Takeda/Protagonist's rare blood cancer drug, Juul's next-gen vaping system, and Lilly's Mounjaro cardiovascular expansion — while 16 Endpoints News articles were blocked by soft paywall. Patent litigation and digital health M&A round out the batch.
Seven articles from five sources covering multiple FDA approvals in rare blood disorders and autoimmune disease, a UK NICE funding decision for transplant technology, and the discontinuation of a BioNTech/Genentech personalized cancer vaccine trial.
Sixteen articles from 7 sources covering BioNTech and Genentech's discontinued personalized cancer vaccine trial, AusperBio's $120M Series C for hepatitis B, BioXcel's bankruptcy filing with Teva asset sale, Genentech's $1B ADC deal with DualityBio, and FDA activity on Priovant's LISRAYA and a novel glaucoma drug.
Revolution Medicines scores FDA approval for pancreatic cancer drug Rasonque, Roche gets companion diagnostic nod for Ziihera, AstraZeneca-Amgen Tezspire wins Phase 3 in eosinophilic esophagitis, and China's Jiangsu province pledges support for pharma M&A.
Twenty articles from eight sources covering FDA approvals in pancreatic cancer and gastric cancer, biotech dealmaking including Biohaven's $795M epilepsy alliance and ARCH/Haisco's China expansion, gene therapy setbacks for Regenxbio, and new clinical data for Argenx's Vyvgart.
A packed Tuesday harvest of 49 articles across 8 sources, led by FDA actions including J&J's Imaavy approval for rare anemia, Jazz's Ziihera in gastric cancer, Masimo's wearable ketone monitor authorization, and Cellenkos' fast track for ALS. Deal activity includes McKesson's $2.5B CRO acquisition, Metsera's $1.5B inflammatory disease deal, and Haisco's $1.5B China immunology play.
Roche's multi-billion-dollar pact with Hanmi for a muscle-conserving obesity drug headlines today's harvest of 29 articles across 10 sources. FDA activity dominates with an Avulux De Novo authorization, Implantica's RefluxStop PMA approval, an Osteal rejection, and an REGENXBIO clinical hold. Eisai launches Leqembi Iqlik in the US while Alzheimer's diagnostics advance with Roche and Quest pTau217 tests.
Three articles from BioSpace and PR Newswire cover Roche's $750M Oregon manufacturing expansion for obesity drugs, Capricor facing activist pressure ahead of an FDA decision on its Duchenne therapy, and Implantica's FDA approval for the RefluxStop GERD device.
Today's harvest includes 42 articles from 10 sources, covering FDA approvals, clinical trials, M&A deals, and industry leadership changes.
32 articles harvested across 8 sources covering FDA approvals (Ultragenyx gene therapy, Implantica RefluxStop, C2N diagnostics), the Heidi Overton FDA nomination, Sandoz-Henlius biosimilars deal, Sanofi-Blueprint layoffs, and the Werewolf-Ambros reverse merger.
August 20 harvest brings 38 articles across 8 sources, led by Moderna and Merck's melanoma vaccine data showing significant recurrence reduction. FDA approvals for Ultragenyx gene therapy and Regeneron's rare bone disease drug round out a busy regulatory day.
Merck-Moderna's personalized cancer vaccine hits Phase 3, Novo and Lilly duel in oral obesity, Enveda's exercise-mimicking pill clears early trials, and the FDA issues warning letters to overseas manufacturers.
25 articles from 8 sources covering $435M+ in M&A deals, FDA regulatory moves including a generative AI device framework, clinical setbacks at Regeneron and EyePoint, and a bullish CDMO outlook driven by recovering biotech funds.
Today's harvest covers AstraZeneca discontinuing its volrustomig bispecific in lung cancer alongside separate Tagrisso/Enhertu wins, Summit/Akeso's ivonescimab China approval with a smaller-than-expected survival benefit, Eli Lilly's $370M OmniAb deal, EyePoint's AMD Phase 3 fail, Argenx's Vyvgart Hytrulo Phase 3 in myositis, and a slate of reverse-merger and funding items. 11 new company profiles were created (Eyepoint, Sandoz, Henlius, Fulcrum, Evaxion, AbelZeta, Akesobio, Abcuro, Redx, Cytokinetics, Acurx).
After filtering, only 3 biopharma-relevant items made the cut on 2026-08-16: an FDA reclassification proposal that affects Photocure's blue light cystoscopy franchise, a successful USFDA inspection at Aurisco Pharmaceutical (generic oligonucleotides), and a MedCity News op-ed on AI terminology in pharma. 4 new company profiles were written (aap Implantate, Photocure, Virchow Medical, BetterLife Pharma).
Nine fresh items from Pharmaphorum, Fierce Pharma, Fierce Biotech, BioSpace, and MedCity News spanning an FDA approval for BMS's CELMoD franchise, Skye-Redx's $125M combination into Fibrx Therapeutics, Capricor's regulatory lifeline for its Duchenne therapy, Definium's Phase 3 LSD win, and England's progress toward hepatitis C elimination.
Today's harvest is 34 articles from 9 sources, headlined by Bristol Myers Squibb's first CELMoD approval (Zenbexus for multiple myeloma), Ovid/Takeda's soticlestat spinning out into a Perceptive-backed $294M NewCo, and MapLight Therapeutics' all-in pivot to its Phase 3-ready schizophrenia asset at the expense of preclinical work.
Today's harvest is 22 articles from 6 sources, headlined by Taiho/Cullinan's zipalertinib Phase 3 win (lining up a Rybrevant contest), Eli Lilly's first retatrutide black-market lawsuits, and Sangamo's $161M bankruptcy asset sale to Lilly/PTC.
Today's harvest spans 33 articles from 8 sources, headlined by Definium's Phase 3 LSD anxiety win, BridgeBio's ATTR ascent as Alnylam stumbles, and AbbVie/Novartis/BMS filing 340B lawsuits in Illinois.
Today's harvest spans 38 articles across 8 sources, led by three major venture rounds (Vaderis $152M Series B, Epicrispr $90M, Infinimmune $75M Series A backed by Regeneron). FDA activity dominates with rejections of ITM Isotope's radiopharma and Scholar Rock's SMA filing, while BMS commits $2.3B to a Houston manufacturing campus.
Curium’s $8bn Lantheus bid, Jazz-Actio at $1.3bn, FDA clears Moderna’s mRNA flu shot and expands Pluvicto, Sionna failure hands Vertex a CF windfall, Silence posts Ph2 blood-cancer data, and Silence Therapeutics’ gene-silencing win in rare blood cancer. The week also brings Psychedelic Breakthrough sightings, Novo-Amazon AI hub, AZ/CSPC China plant, Merck KGaA tariff relief, and Replimune’s melanoma approval after a yearlong regulatory battle.
A quiet Sunday harvest surfaces a single new item — the STAT Readout newsletter exploring Boston's loss of biotech dominance to Silicon Valley — while a Medicare policy shift and Alzheimer's tau research round out the newsletter's key themes.
14 stories from 7 sources covering FDA regulatory actions (Moderna flu vaccine, Galibra orphan designation, RiboX IND clearance), IPO activity (Braveheart $382M, BlossomHill/Latigo), biotech restructuring (Ensoma layoffs), and ongoing 340B policy battles.
FDA approvals for Moderna's mRNA flu vaccine and Replimune's melanoma therapy headline today's harvest. IPO momentum continues (Attovia $289M, Braveheart $382M), while Supernus-Indivior and Tarsus-Alkeus deals, BioMarin's phase 3 miss, and an Alnylam earnings plunge round out a busy session.
Nineteen fresh items across 8 sources: Moderna's mRNA flu vaccine wins FDA approval, Braveheart and Tarsus make big market moves, LifeMine raises $263M, Emergent restructures, and the FDA approves the first full-spectrum narcolepsy Type 1 treatment.
Big pharma Q2 earnings dominate (Lilly's $23B beat, Novo's pipeline setbacks, Gilead's diversification push), Amgen trims an early obesity program, Supernus and Indivior agree to merge, the FDA approves Mucinex's first OTC cold-and-flu innovation in 14 years, and AI keeps moving into clinical development.
Sixteen fresh items across five sources today: Pfizer axes an ex-Metsera obesity asset, Merck logs a mid-stage win and miss from its Prometheus bet, KKR inks a $5.7B take-private of Integer, Latigo sets $247M IPO terms, Lisata cuts 72% of staff, and the Congo Ebola outbreak passes 1,700 deaths.
Supernus-Indivior $2.2B CNS merger, AZ-BMS merger talks per FT, Curium's ~$8B Lantheus buy, Lilly-Resilience $750M device investment, BlossomHill and Apnimed IPOs, Amgen cloud breach, and Novo's Phase 3 IL-6 setback headline the day.
Seven Endpoints News items covering Novo Nordisk's late-stage cardiovascular failure, AbbVie's Skyrizi-driven guidance raise, Moderna's norovirus readout delay, Alnylam's Q2 slump, the 340B rebate pilot, and pharma tariff timing.
48 articles from 7 sources covering FDA regulatory activity, corporate earnings, deal activity, and policy developments in biopharma.
Today's biopharma news cycle spans Apnimed's $192M IPO, Alnylam's full-year guidance cut, Replimune and Capricor adcomm fallout, Sanofi's pipeline concerns after weak Dupixent-dependent earnings, plus the FDA's first freeze-dried plasma product license. Sixty articles across ten sources.
44 fresh articles harvested across BioSpace, Endpoints, STAT and FDA Newsroom on 2026-07-30. Top clusters: Capricor/Replimune FDA adcomms (2 rejections), J&J-Sail $2.58B CAR-T option, Sanofi €1B write-off + new CEO R&D reset, AtaiBeckley pre-Lilly $2.8B deal context, and a wave of Q2 earnings across BMS/Regeneron/UCB/Ipsen.
Forty-three fresh articles from eleven sources on 2026-07-29, with Q2 earnings (Biogen, Leqembi), FDA actions (Replimune staff review, Hengrui citations, generic weight-loss guidance, Viatris contraceptive approval), and a fresh round of reverse-merger listings. Notable: J&J $5.5B talc proposal, Eli Lilly tops productivity ranking, Vertex pays AbCellera $28M for autoimmune TCE.
GSK's £2.5B three-year cost-saving plan dominated the trade-press conversation with five convergent headlines spanning mature-product targeting, R&D consolidation, and a £1.33B cough-trial write-down; Altimmune's GLP-1/GIP dual scored an 'unequivocal' Phase 2 in heavy drinking, opening the alcohol-use-disorder lane; Novo Holdings-backed Claris Bio and RA Capital-launched Oak Hill Bio each closed their debut rounds on the same morning; the FDA's July adcomm slate — Replimune, Capricor, six wellness peptides — previewed a busy late-summer advisory committee cycle; Outlook Therapeutics finally won FDA approval of Lytenava after three prior CRLs.
AstraZeneca led the day with three convergent signals — solid Q2, ADC pipeline discipline, and an AI-led late-stage trial strategy; Sarepta and Legend Biotech both announced abrupt CEO transitions; Argenx paid $2.2B for Forte Biosciences and its Phase 2 vitiligo candidate; the FDA recommitted to advisory committees while Dexcom became the first to join a new FDA/CMS health-tech pilot.
Today's harvest from BioSpace, Fierce Pharma, Fierce Biotech, and STAT News surfaces two Amgen stories (FDA appeal for Tavneos, ~40 layoffs) plus a Roche Q2 pipeline update from CEO Schinecker and a Fierce Biotech study flagging genetic risk markers in Yescarta patients.
Nineteen articles from 9 sources harvested between 2026-06-25 and 2026-07-25. Coverage clusters around FDA advisory panels (peptide compounding, Amgen's Tavneos defense), major oncology approvals (GSK's $10.6B bet), the Novo-Lilly ad-suit escalation, and Venus Medtech's trilingual TAVR enrollment milestone. The week's biggest missing beat: no AI-bio clinical readouts.
A daily synthesis of the 63 biopharma news items the OpenBio News harvest cron pulled this morning: Trump's renewed tariff threat on generic drugs not made in the US, FDA adcomm voting in favor of lifting restrictions on BPC-157, Scribe Therapeutics' $129M IPO, Lundbeck's Fast Track for an orexin-2 narcolepsy drug, Roche's FDA clearance for cobas BV/CV, FDA leadership transitions under the new commissioner, Repligen's $1.5B BioLife buy, and 18 newly-tagged mid-cap companies.
A daily synthesis of the 26 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Jideytro (zidesamtinib) for ROS1-positive NSCLC validating GSK's $10.6B Nuvalent acquisition, Lilly's triple-G agonist hitting 22% weight loss in Phase 3, J&J's bispecific combination delivering 89% PFS in multiple myeloma, Roche's late-stage pipeline confidence, Sanofi FDA untitled letter over Beyfortus, FDA TEMPO digital health pilot selection, Scancell/Neuphoria reverse merger, BeOne's $300M U.S. manufacturing expansion, and a Merck Ebola vaccine trial in the DRC.
Today's 49-article harvest covers Merck's oral PCSK9 launch, Lilly's $2.8B AtaiBeckley deal, Agios's sickle cell disappointment, FDA's PreCheck manufacturing pilot, and AstraZeneca's Wainua flop.
Today's harvest (32 new news files + 6 new company JSONs) covers five threads that stood out: Gilead + Merck's Phase 3 data backing a first weekly oral HIV pill, Agios dropping its next-gen sickle cell candidate, Samsung Biologics' $1.8B PolyPeptide buyout, a wave of US-biotech Hong Kong IPOs (Axiom), and the Novo-Lilly GLP-1 ad fight. FDA activity ran hot: 14 new CRLs released, a third rejection for Hengrui-Elevar's liver cancer combo, and the FDA's radical-transparency policy running into legal uncertainty. Smaller beats: Novartis geography-agnostic on China deals, Moderna-CureVac patent litigation, Scholar Rock's apitegromab site-classification wait, and Tempus AI's $1.5B Personalis buy. Tier 1 cron additions: jupiter-neurosciences, scholar-rock, legend-biotech, agios-pharmaceuticals, samsung-biologics, tempus-ai. STAT News and BioSpace both ran opinion pieces that the political-filter dropped at parse time.
Today's recovered batch (46 new news files, recovered from the 9 AM PT cron that aborted mid-write) covers three threads that stood out: Eli Lilly's $3.8B psychedelics move via AtaiBeckley, Samsung Biologics' $1.8B all-cash bid for PolyPeptide, and two parallel AI-supercomputer announcements (BMS with Nvidia, BMS-Nvidia separate coverage). Other themes: Novo's oral Wegovy cleared in the EU, Merck's oral PCSK9 (enlicitide) becoming the first oral option in the cholesterol-lowering PCSK9 class, German lawmakers' cost-savings bill that drugmakers warn will drive R&D out, FDA's CRL-release pause, the EU's Sanofi flu-vaccine antitrust probe, FDA's psychedelic-guidance finalization, and Camurus's CAM2029 NDA resubmission acceptance. Endpoints News contributed the largest share (15 articles) but with notable paywall filtering; STAT News's editorial surface ran warm on political/healthcare-policy commentary that the cron filtered at parse time per Rule 7.
Today's harvest (8 new news files + 1 new company JSON) is unusually thin on the heavy trade-press beats — Endpoints News contributed 16 candidates but every URL was gated by its soft paywall, and STAT News's editorial surface ran warm on politically charged healthcare items that the cron filtered out at parse time. The day's write-eligible set clusters on three narrower threads: a topical skin-closure product launch from BRIJ Medical (BRIJ-SEAL™), a small set of federal-healthcare / professional-society items (APhA's FDA comments on peptide substances, Presage's FedRAMP authorization via Kno2, Salus Scientific's burn-care consensus welcome), and two device-business items (Poriferous's DuraBloc patent, ANF Care's US wearable launch). One STAT international public-health story (WHO pressing Uganda on Marburg updates) and one borderline healthcare-policy item (Medicare smoking-cessation coverage expansion) round out the day.
Today's harvest (10 articles) clusters around three themes: a continued biotech IPO wave with Braveheart, Attovia, Vogenx, and BlossomHill pricing deals; the FDA's approval of the first oral PCSK9 inhibitor (Merck's Lipfendra / enlicitide) and the full approval of Novartis's Fabhalta in IgAN; and a pair of late-stage M&A developments — the Jasper Therapeutics all-stock merger with Kira Pharmaceuticals, and Eli Lilly's $2.8B acquisition of AtaiBeckley. Endpoints News contributed 20 candidates but every URL is gated by Endpoints' soft paywall; political/healthcare-policy items (transgender care, CDC confirmation, vaccine injury claims, China biotech restrictions, CMS GLOBE/GUARD litigation) were filtered at parse time.
GSK culls a $2B Bellus chronic-cough drug after Phase 3 failure; Celcuity's Revtorpyk wins FDA breast cancer approval; biotech IPO filings accelerate (Braveheart, Attovia, BlossomHill) and M&A stays heavy with Lilly's $2.8B AtaiBeckley psychedelics buyout and Dimerix's $292M Mission kidney deal.
A daily synthesis of the 39 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Merck's oral PCSK9 inhibitor Lipfendra, two parallel Lilly psychedelic buyouts (AtaiBeckley, ~$2.8-3.8B), projected 14,000+ H1 biopharma layoffs, Sanofi's mRNA-patent suit against Pfizer and Moderna, an FDA screwworm-drug EUA, and the Vogenx and Braveheart IPO filings.
45 news items harvested from 11 biopharma outlets, covering Kelun-Merck's NSCLC ADC win, biotech IPO momentum, Celcuity's breast-cancer approval, FDA CRL policy resumption, and Bora-Insilico's $2.5B AI partnership.
Today's harvest: 37 fresh news files. Dominant themes: large-pharma dealmaking (Vertex-Crinetics, AstraZeneca-Dizal, Spero-Innovent, Avere-Hansoh, Chai Discovery $400M); the AstraZeneca-Ionis Wainua Phase 3 cardiomyopathy failure landing on three sources; FDA simplification of pharmaceutical manufacturing and registration (three separate articles); FDA approval of Leqembi Iqlik SC starter dose (Biogen/Eisai); and FDA psychedelics guidance finalization. Endpoints News was fully soft-paywalled (28/28 rejected) for the fifth consecutive run; STAT ran political/feature content the editorial filter dropped.
Today's harvest landed 20 fresh news files across 7 sources. The dominant theme is regulatory and deal flow: FDA posted new CRLs days after pausing the disclosure program, Boehringer's nerandomilast (Jascayd) became Europe's first new IPF drug in years, Q32 Bio's anti-IL-7R antibody bempikibart jumped on Phase 2 alopecia data, and AstraZeneca's new Sino Biopharm COPD pact surfaced via MedCity News. Endpoints News was fully soft-paywalled and contributed zero articles this run despite 13 candidates. STAT News and Reuters Biopharma contributed only filtered-out items (political, op-ed, author name, general market).
Today's harvest: 1 fresh news file from BioSpace covering FDA's pause on public release of Complete Response Letters following an April citizen petition. Endpoints remained fully paywalled; STAT ran several politically charged pieces and healthcare-feature columns that the editorial filter dropped; prior-run coverage of AstraZeneca/Ionis/Wainua, Roche/Huntington's, and Bausch+Lomb/glaucoma topic clusters absorbed the remaining fresh candidates.
Today's harvest: 4 fresh news files spanning an FDA approval (Padcev-Keytruda in MIBC), a balance-sheet deal (Bayer-Apollo), a BioMarin patient-marketing push for PKU teens, and a Phase 3 ADC win for the GSK-Hansoh partnership in China. Endpoints soft-paywall and topic duplicates with prior coverage held the headline count down.
Today's harvest adds 26 free biopharma items across 6 sources, led by FDA/regulatory updates, clinical-development signals, China-linked partnerships, financing and M&A coverage, and selected company leadership or manufacturing moves.
56 fresh biopharma items across 7 sources (Endpoints News was fully soft-paywalled today so 37 of its candidates were dropped). BioPharma Dive contributed 17 of the 56 items including Roche KRAS head-to-head, Alkermes CEO succession, MeiraGTx/Oberland $400M financing, and Celea $180M IPF. FDA approvals landed for ENNUMO (Accord BioPharma), Theranica Nerivio coverage, WuXi Biologics PLI approval, and Vera Therapeutics atacicept for IgAN. Alector absorbed GSK's abandoned $700M Alzheimer's collab while Fate's off-the-shelf CAR-T prospect reported early promise in systemic sclerosis.
53 fresh biopharma items across 8 sources. Vertex's $10B Crinetics buy and a $400M MeiraGTx financing headline the day; FDA hands Vanda, Octapharma, and Porton Advanced multiple approval-track wins; Endpoints News is fully paywalled today so the major M&A and 340B stories landed only via Fierce Pharma and BioPharma Dive.
Today's harvest surfaced 3 articles after 30-day + URL-dedupe + political-deny + Tier-2 cross-site collapse. Headlines cluster around Endpoints' second-half M&A kickoff led by Novartis/Vertex/Ipsen with up to $12.6B in new deals on top of a 45-deal H1 2026, BioPharma Dive's coverage of Ipsen's Memo Therapeutics buyout as a rare-disease buildout, and MedCity News's angle on Novartis's Myricx ADC differentiation thesis.
Today's harvest across 11 biopharma news sources surfaced 8 articles after 30-day + URL-dedupe + political-deny + Tier-2 cross-site collapse. Headlines cluster around Novartis's $1.5B Myricx ADC deal, Genentech's 103-job layoff paired with a $490M Astex biobucks pact, Scribe Therapeutics' IPO signal, BridgeBio's Attruby kidney-benefit positioning, Movmedix's US FDA-cleared entry, Celea's $180M IPF pivotal funding, a 5-molecular-glue overview, and a BioSpace H1-2026 FDA retrospective.
Today's harvest across 11 biopharma news sources surfaced only one surviving article after filtering: a BioSpace recap of the BIO 2026 conference in San Diego noting the upbeat dealmaking and IPO sentiment, an evolving FDA posture, and a high-profile retraction of a pivotal study backing Amgen's rare-disease drug Tavneos.
Endpoints News dominates with 38 articles covering Scribe Therapeutics IPO filing, AstraZeneca's CSPC kidney drug deal, and Anthropic's Claude Science launch for pharma. Fierce Biotech contributes 10 articles including United Therapeutics' $140M thymic cell therapy acquisition and Roche's phase 3 lung cancer win.
Today's 50-article harvest clusters around four themes: FDA PreCheck pilot selections and cell/gene therapy approvals (Orca Tregzi, Vertex Casgevy pediatric label, 4DMedical TGA), M&A and licensing consolidation (Ipsen-Kartos, AbbVie-Apogee, Biogen-RayThera, AstraZeneca-CSPC, Theravance $929M buyout, Sixth Street/KKR-BridgeBio $1B), China-anchored deal flow (Pfizer-Innovent insurance, Lilly-Veropharm China, Drugmakers defend Chinese trials), and CDMO/careers signal (Lonza ADC expansion, Kimball EU/India build, 8 companies hiring in Greater Philadelphia). Notable absences: no STAT Plus pieces (paywall), zero FDA newsroom press announcements (all were older than 30 days), Endpoints coverage down to one (soft paywall) and MedCity down to three (anti-bot 403).
Today's harvest produced 46 fresh news files spanning Endpoints News, Reuters Biopharma, PRNewswire, BioSpace, and FDA Newsroom — anchored by FDA's pediatric sickle-cell gene-therapy approval, Roche's KRAS Phase 3 victory over Amgen/BMS, and BridgeBio's $1B launch fundraise, with 8 new company JSONs created.
Today's incremental harvest produced a single new article — BeOne's Brukinsa hitting its primary endpoint in a Phase 3 mantle-cell-lymphoma confirmatory trial — while 19 of 20 candidates were already represented in the news folder, reflecting a backlog-cleanup pattern with 20-article candidates against 1 truly new piece.
FDA PreCheck Pilot Program with Lilly and Regeneron headlined a heavy regulatory day; Sobi and Unicycive received new CRLs for contract manufacturing; Viridian's Lumvoa approved to challenge Amgen's Tepezza; Zymeworks to acquire Theravance for $929M.
Nine fresh items harvested from the four biopharma homepages on 2026-06-29, with M&A headlines (Zymeworks-Theravance, Ipsen-Kartos), a Sobi CRL on both Fierce Pharma and Endpoints, and a Viridian FDA approval / market debut dominating the cycle. Industry-volume is moderate, with FDA activity, M&A, and one clinical-failure news.
Five fresh items harvested from the four biopharma homepages on 2026-06-28, with FDA approvals and a CMO warning letter dominating the cycle. Industry-volume is light post-BIO 2026 and pre-Q2 earnings season.
A daily synthesis of the 10 biopharma news items the OpenBio News harvest cron pulled this morning: FDA advisory panel scheduling for Replimune and Capricor, a Viridian eye-drug approval framed as competition with Amgen's Tepezza, a SCOTUS Roundup ruling and its two-day aftermath, the GSK new-CEO buyout, Pfizer-Seagen cooling vs. a Pfizer-Innovent China pact, a 'historic' solid-tumor CAR-T nod, and an Ebola case count crossing 1,000 in Congo.